Total Funding
15
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.
- Laura E. Benjamin: CEO & President
- David Malek: Chief Business Officer
About the Company
OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.
OncXerna Therapeutics is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company’s deep understanding of how to prospectively identify patients based on the dominant biology of their tumor
microenvironments. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies with known mechanisms of action that directly address these biologies, to dramatically improve patient outcomes.
The company was founded in 2018 and was formerly known as Oncologie.
Women Founded
Women Led
